PriceTargets.com logo

Invitae - NVTA Stock Price Target and Predictions

  • Consensus Rating: Strong Sell
  • Consensus Price Target: $1.00
  • Forecasted Upside: 99,900.00%
  • Number of Analysts: 3
  • Breakdown:
  • 3 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 04/24/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for NVTA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Invitae Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NVTA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NVTA

Analyst Price Target is $1.00
▲ +99,900.00% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Invitae in the last 3 months. The average price target is $1.00, with a high forecast of $1.50 and a low forecast of $0.50. The average price target represents a 99,900.00% upside from the last price of $0.00.

This chart shows the closing price for NVTA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Strong Sell

The current consensus among 3 contributing investment analysts is to strong sell stock in Invitae. This Strong Sell consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 3 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 3 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 3 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 3 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 3 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 3 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 3 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 3 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 3 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/20/2023The Goldman Sachs GroupLower TargetSell ➝ Sell$1.00 ➝ $0.50Low
8/15/2023Piper SandlerLower TargetUnderweight ➝ Underweight$1.50Low
7/21/2023The Goldman Sachs GroupLower TargetSell$1.50 ➝ $1.00Low
5/15/2023Piper SandlerLower Target$1.75 ➝ $1.50Low
5/15/2023Raymond JamesDowngradeMarket Perform ➝ UnderperformLow
3/3/2023Piper SandlerLower TargetUnderweight$2.25 ➝ $1.75Low
1/31/2023The Goldman Sachs GroupDowngradeNeutral ➝ Sell$2.00Low
11/15/2022CowenBoost Target$2.80N/A
11/9/2022SVB LeerinkBoost TargetMarket Perform$2.50 ➝ $3.00Low
11/8/2022William BlairReiterated RatingMarket PerformLow
8/24/2022Credit Suisse GroupInitiated CoverageUnderperformLow
8/10/2022JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightLow
7/26/2022CowenDowngradeOutperform ➝ Market PerformLow
7/26/2022CowenDowngradeOutperform ➝ Market PerformLow
7/21/2022Raymond JamesDowngradeOutperform ➝ Market PerformLow
7/20/2022LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralLow
7/19/2022CowenLower TargetOutperform$10.00 ➝ $8.00Low
7/19/2022CowenLower Target$10.00 ➝ $8.00Low
7/19/2022SVB LeerinkDowngradeOutperform ➝ Market PerformLow
7/19/2022BenchmarkDowngradeBuy ➝ HoldLow
6/13/2022BenchmarkLower TargetBuy$13.00 ➝ $6.00High
6/2/2022Piper SandlerInitiated CoverageUnderweightHigh
5/4/2022Raymond JamesLower Target$10.50 ➝ $8.50High
4/19/2022The Goldman Sachs GroupLower TargetNeutral$14.00 ➝ $10.00High
4/18/2022Raymond JamesLower TargetOutperform$15.00 ➝ $10.50High
2/28/2022Raymond JamesLower TargetOutperform$36.00 ➝ $15.00High
2/25/2022SVB LeerinkLower TargetOutperform$30.00 ➝ $25.00High
2/15/2022Morgan StanleyLower TargetEqual Weight$37.00 ➝ $18.00Medium
11/9/2021Wells Fargo & CompanyLower TargetEqual Weight$35.00 ➝ $25.00High
11/9/2021Raymond JamesLower TargetOutperform$38.00 ➝ $36.00High
9/9/2021SVB LeerinkReiterated RatingBuyHigh
8/5/2021Morgan StanleyLower TargetEqual Weight$41.00 ➝ $40.00Medium
8/4/2021BenchmarkUpgradeHold ➝ Buy$35.00High
6/21/2021Wells Fargo & CompanyBoost TargetEqual Weight$30.00 ➝ $35.00Low
6/15/2021Raymond JamesInitiated CoverageOutperform$37.00Medium
6/3/2021The Goldman Sachs GroupInitiated CoverageNeutral$33.00High
5/25/2021Wells Fargo & CompanyInitiated CoverageEqual Weight$30.00High
5/6/2021Morgan StanleyLower TargetEqual Weight$45.00 ➝ $41.00High
5/5/2021SVB LeerinkLower TargetOutperform$65.00 ➝ $50.00High
4/11/2021SVB LeerinkReiterated RatingBuyLow
4/5/2021OppenheimerUpgradeMarket Perform ➝ Outperform$48.00High
2/25/2021Morgan StanleyBoost TargetEqual Weight$41.00 ➝ $45.00High
2/18/2021SVB LeerinkBoost TargetOutperform$64.00 ➝ $65.00High
2/18/2021LADENBURG THALM/SH SHUpgradeNeutral ➝ Buy$46.50 ➝ $58.00High
2/1/2021OppenheimerDowngradeOutperform ➝ Market PerformLow
1/20/2021SVB LeerinkBoost TargetOutperform$48.00 ➝ $64.00Low
11/6/2020Morgan StanleyBoost TargetEqual Weight$38.00 ➝ $41.00Medium
11/6/2020LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralLow
11/3/2020SVB LeerinkBoost TargetOutperform$34.00 ➝ $44.00High
10/14/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$45.00High
10/5/2020OppenheimerBoost Target$37.00 ➝ $48.00Medium
9/9/2020Morgan StanleyInitiated CoverageEqual Weight$38.00High
8/5/2020LADENBURG THALM/SH SHBoost TargetBuy$31.25 ➝ $37.25High
8/5/2020SVB LeerinkLower TargetOutperform$40.00 ➝ $34.00High
8/4/2020OppenheimerInitiated CoverageBuy$37.00High
7/21/2020OppenheimerInitiated CoveragePositive ➝ Buy$29.00 ➝ $37.00Low
7/15/2020SVB LeerinkBoost TargetOutperform$25.00 ➝ $40.00Medium
7/1/2020BenchmarkDowngradeBuy ➝ HoldMedium
6/26/2020CowenBoost TargetOutperform$18.00 ➝ $35.00Medium
6/22/2020OppenheimerReiterated RatingBuy$29.00High
5/6/2020SVB LeerinkBoost TargetOutperform$20.00 ➝ $25.00High
4/8/2020BenchmarkLower TargetBuy$31.00 ➝ $20.00High
4/2/2020OppenheimerLower Target$32.00 ➝ $25.00High
2/20/2020CowenBoost TargetOutperform ➝ In-Line$20.00 ➝ $30.00High
8/25/2019Chardan CapitalSet TargetBuy$32.00High
8/7/2019SVB LeerinkSet TargetBuy$31.00Medium
8/7/2019OppenheimerSet TargetBuy$34.00Medium
8/7/2019BenchmarkReiterated RatingBuy ➝ Buy$26.00 ➝ $28.00High
7/12/2019BenchmarkBoost TargetBuy$22.00 ➝ $26.00Low
6/11/2019Chardan CapitalReiterated RatingBuy$30.00High
(Data available from 4/26/2019 forward)

News Sentiment Rating

-0.16 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
9/28/2023
  • 3 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
Mentions as of
10/28/2023
  • 2 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 2 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
1/26/2024
  • 2 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Invitae logo
Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $0.00
Low: $0.00
High: $0.00

50 Day Range

MA: $0.01
Low: $0.00
High: $0.02

52 Week Range

Now: $0.00
Low: $0.02
High: $0.02

Volume

178,541 shs

Average Volume

23,716,614 shs

Market Capitalization

$267.01 thousand

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.59

Frequently Asked Questions

What sell-side analysts currently cover shares of Invitae?

The following Wall Street analysts have issued stock ratings on Invitae in the last twelve months: Piper Sandler, Raymond James, StockNews.com, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for NVTA.

What is the current price target for Invitae?

2 Wall Street analysts have set twelve-month price targets for Invitae in the last year. Their average twelve-month price target is $1.00, suggesting a possible upside of 99,900.0%. Piper Sandler has the highest price target set, predicting NVTA will reach $1.50 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $0.50 for Invitae in the next year.
View the latest price targets for NVTA.

What is the current consensus analyst rating for Invitae?

Invitae currently has 3 sell ratings from Wall Street analysts. The stock has a consensus analyst rating of "Strong Sell."
View the latest ratings for NVTA.

What other companies compete with Invitae?

Other companies that are similar to Invitae include Aclarion, Acorda Therapeutics, Akanda, Sintx Technologies and Bone Biologics. Learn More about companies similar to Invitae.

How do I contact Invitae's investor relations team?

Invitae's physical mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company's listed phone number is (628) 213-3369 and its investor relations email address is [email protected]. The official website for Invitae is www.invitae.com. Learn More about contacing Invitae investor relations.